Neutral News Coverage Extremely Likely to Impact AstraZeneca (AZN) Stock Price
News articles about AstraZeneca (NYSE:AZN) have trended neutral on Thursday, according to InfoTrie. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. AstraZeneca earned a news sentiment score of 0.11 on their scale. InfoTrie also gave news coverage about the company an news buzz score of 10 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company’s share price in the next several days.
These are some of the media stories that may have impacted AstraZeneca’s analysis:
- AstraZeneca among repeat offenders sparking shareholder anger (citywire.co.uk)
- [$$] ‘Repeat offender’ companies warned of fresh investor onslaught (finance.yahoo.com)
- GlaxoSmithKline Capital Inc. — Moody’s changes GSK’s outlook to negative; affirms A2 ratings (finance.yahoo.com)
- Could AstraZeneca boost your retirement income as the State Pension age rises? (aol.co.uk)
- AstraZeneca (AZN) Receives Daily Coverage Optimism Rating of 0.11 (americanbankingnews.com)
AZN has been the subject of several analyst reports. Jefferies Financial Group downgraded shares of AstraZeneca from a “buy” rating to a “hold” rating in a research report on Thursday, August 16th. Guggenheim initiated coverage on shares of AstraZeneca in a research report on Monday, October 8th. They set a “buy” rating for the company. HSBC reissued a “sell” rating on shares of AstraZeneca in a research report on Monday, November 12th. Wolfe Research initiated coverage on shares of AstraZeneca in a research report on Tuesday, October 23rd. They set an “outperform” rating for the company. Finally, Zacks Investment Research downgraded shares of AstraZeneca from a “buy” rating to a “hold” rating in a research report on Tuesday, October 16th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and seven have issued a buy rating to the company’s stock. AstraZeneca presently has a consensus rating of “Hold” and an average target price of $41.74.
AstraZeneca (NYSE:AZN) last issued its earnings results on Thursday, November 8th. The company reported $0.71 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.33 by $0.38. AstraZeneca had a net margin of 11.29% and a return on equity of 27.32%. The company had revenue of $5.34 billion for the quarter, compared to analysts’ expectations of $5.26 billion. During the same quarter last year, the company posted $1.12 earnings per share. The firm’s quarterly revenue was down 14.3% on a year-over-year basis. On average, sell-side analysts anticipate that AstraZeneca will post 1.68 EPS for the current fiscal year.
In related news, major shareholder Plc Astrazeneca bought 246,666 shares of the company’s stock in a transaction that occurred on Friday, September 28th. The shares were bought at an average price of $15.00 per share, for a total transaction of $3,699,990.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
ILLEGAL ACTIVITY WARNING: This article was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.watchlistnews.com/neutral-news-coverage-extremely-likely-to-impact-astrazeneca-azn-stock-price/2663332.html.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Read More: Understanding the different types of bonds
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.